Skip to content
Screener

Cognex CGNX Research, Development and Engineering Expenses — Stock-Based Comp

Similar metrics at other companies

Scotts Miracle-Gro logo
SMGHawthorne — Stock-Based Comp
$650K-50.9%
Spectrum Brands Holdings logo
SPBGPC — Stock-Based Comp
$0
Spectrum Brands Holdings logo
SPBHPC — Stock-Based Comp
$400K
Credo Technology Group Holding Ltd logo
CRDOReportable Segment — Stock-Based Comp
$50.76M+84.6%
Summit Therapeutics logo
SMMTReportable Segment — Stock-Based Comp
$72.79M+556%
QXO, Inc. logo
QXOReportable Segment — Stock-Based Comp
$39.2M+94.1%

Other financials

Income statement

See full
Revenue$291.3M+16.9%
Gross profit$205.8M+22.6%
Operating income$85.5M+96.9%
Net income$72.8M+79.6%
EPS (diluted)$0.43+79.2%

Balance sheet

See full
Cash & equivalents$302.5M+68.7%
Total debt$72.5M-12.9%
Total equity$1.6B+8.2%
Total assets$2.2B+8.7%

Cash flow

See full
Operating cash flow$69.2M+62.2%
CapEx$1.5M-30.2%
Free cash flow$67.6M+67.3%

Valuation

See full
Market cap$11.77B+71.4%
Enterprise value$11.54B+70.4%
P/E67.3×+11.1×
P/S10.8×+3.4×

Profitability

See full
Gross margin68.9%+1.2pp
Operating margin21.9%+7.7pp
Net margin16.1%+2.9pp
FCF margin24.6%+5.3pp

Returns & leverage

See full
Return on equity11.1%+3.0pp
Debt / equity0.0×
Current ratio3.9×+0.6×

Where this comes from

Reported directly by Cognex in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Cognex’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000851205-26-000065
Line itemThree-months Ended / July 5, 2026Three-months Ended / June 29, 2025Six-months Ended / July 5, 2026Six-months Ended / June 29, 2025
Research, development, and engineering expenses
Salaries and fringe benefits18,96519,55738,03937,831
Incentive compensation (2)2,2962,3684,3203,439
Stock-based compensation3,3883,4438,4828,139
Depreciation and amortization4727379741,492
Other segment expenses (3)7,2706,99717,60116,928
Total research, development, and engineering expenses32,39133,10269,41667,829
Selling, general, and administrative expenses

Item 1. Financial Statements (interim periods unaudited)

FAQ

What is Cognex's research, development and engineering expenses — stock-based comp?
Cognex (CGNX) reported research, development and engineering expenses — stock-based comp of $3.39M in Q2 2026.
How has Cognex's research, development and engineering expenses — stock-based comp changed year-over-year?
Cognex's research, development and engineering expenses — stock-based comp decreased by 1.6% year-over-year, from $3.44M to $3.39M.
What is the long-term trend for Cognex's research, development and engineering expenses — stock-based comp?
Over 3 years (2022 to 2025), Cognex's research, development and engineering expenses — stock-based comp has grown at a -4.7% compound annual growth rate (CAGR), from $17.69M to $15.34M.
What does research, development and engineering expenses — stock-based comp mean?
This metric represents the non-cash expense associated with equity-based awards granted to employees within the research, development, and engineering functions. It reflects the cost of using stock options or restricted stock units to attract and retain technical talent. Monitoring this helps investors understand the dilution impact and the long-term alignment of the engineering workforce with shareholder interests.

Ask your AI about Cognex's research, development and engineering expenses — stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude